Stoke Therapeutics (NASDAQ:STOK) Releases Earnings Results, Beats Estimates By $0.38 EPS

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) issued its earnings results on Monday. The company reported ($0.18) EPS for the quarter, topping analysts' consensus estimates of ($0.56) by $0.38, Zacks reports. The firm had revenue of $22.61 million during the quarter, compared to the consensus estimate of $4.20 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%.

Stoke Therapeutics Stock Down 2.2 %

NASDAQ STOK traded down $0.18 during trading hours on Friday, hitting $8.15. 1,407,236 shares of the stock were exchanged, compared to its average volume of 841,139. The company has a market cap of $431.68 million, a price-to-earnings ratio of -3.88 and a beta of 0.99. Stoke Therapeutics has a 12-month low of $5.93 and a 12-month high of $17.58. The stock has a 50-day moving average of $9.47 and a 200 day moving average of $11.45.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on STOK. Chardan Capital restated a "buy" rating and issued a $24.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday. Cantor Fitzgerald restated an "overweight" rating on shares of Stoke Therapeutics in a research note on Tuesday, December 10th. HC Wainwright restated a "buy" rating and issued a $47.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday. Finally, Needham & Company LLC restated a "buy" rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a research note on Tuesday. One analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $23.00.

Remove Ads

Insider Buying and Selling

In other Stoke Therapeutics news, Director Edward M. Md Kaye sold 10,382 shares of the stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $90,011.94. Following the completion of the transaction, the director now directly owns 148,253 shares of the company's stock, valued at approximately $1,285,353.51. This trade represents a 6.54 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Barry Ticho sold 3,884 shares of the stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $33,674.28. Following the completion of the transaction, the insider now directly owns 63,962 shares of the company's stock, valued at approximately $554,550.54. This trade represents a 5.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 16,532 shares of company stock valued at $143,332 over the last ninety days. Corporate insiders own 11.30% of the company's stock.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.